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RANK Is Expressed in Metastatic Melanoma and
Highly Upregulated on Melanoma-Initiating Cells
Verena Kupas1, Carsten Weishaupt1, Dorothee Siepmann1, Maria-Laura Kaserer1, Mareike Eickelmann1,
Dieter Metze1, Thomas A. Luger1,2, Stefan Beissert1,2 and Karin Loser1,2
Melanoma accounts for B79% of skin cancer-related deaths, and the receptor activator of NF-kB
(RANK)–receptor activator of NF-kB ligand (RANKL) pathway has been shown to be involved in the migration
and metastasis of epithelial tumor cells. In this study, we demonstrate that RANK was significantly increased in
peripheral circulating melanoma cells, primary melanomas, and metastases from stage IV melanoma patients
compared with tumor cells from stage I melanoma patients. However, upregulated RANK expression was not
found in stage IV melanoma patients with bone metastases compared with stage IV melanoma patients without
bone metastases, providing a possible explanation for the clinical observation that melanoma cells do not
preferentially metastasize to bone tissue. Strikingly, RANK-expressing melanoma cells from peripheral blood,
primary tumors, or metastases of stage IV patients coexpressed ATP-binding cassette (ABC) B5 and CD133, both
markers characteristic of melanoma-initiating cells, suggesting a tumor stem cell–like phenotype. In support of
this hypothesis, RANK-expressing melanoma cells showed a reduced Ki67 proliferation index compared with
RANK melanoma cells from the same patient and are able to induce tumor growth in immunodeficient mice.
Together, our data demonstrate that RANK expression is increased in metastatic melanoma and highly
upregulated on melanoma-initiating cells, suggesting that RANK might be involved in the development and
maintenance of melanoma-initiating cells and possibly in metastatic spreading.
Journal of Investigative Dermatology (2011) 131, 944–955; doi:10.1038/jid.2010.377; published online 27 January 2011
INTRODUCTION
Malignant melanoma (MM) is one of the most lethal and
widely metastasizing cutaneous malignancies. The incidence
of MM is constantly rising, and, although it accounts for only
4% of skin cancer cases, it causes B79% of skin cancer–
related deaths (Essner et al., 2006; Kochhar et al., 2009). Up
to 20% of MM patients develop metastases with a median
survival after the appearance of distant metastases between 6
and 9 months (Houghton et al., 1998; Kochhar et al., 2009).
In prostate, breast, or renal cancer, it has been shown that
interactions of the receptor activator of NF-kB (RANK,
CD265) with its ligand (RANKL, also known as TRANCE or
CD254) are critically involved in metastasis formation (Bhatia
et al., 2005; Chen et al., 2006; Jones et al., 2006; Mikami
et al., 2009). Upregulated RANK and RANKL expression has
been observed in surgical biopsy samples from metastatic
prostate cancer patients, and increased RANK levels were
correlated with more aggressive and advanced prostate
carcinomas (Chen et al., 2006). Similar observations were
made in renal cell carcinoma patients, in that elevated RANK
expression serves as a significant predictor of recurrence,
metastasis, and poor prognosis (Mikami et al., 2009).
Progression and metastasis of solid tumors are driven by a
minority population of tumor-initiating cells that migrate from
the primary tumor into surrounding tissues, blood, and lymph
vasculature (Schatton and Frank, 2007; Smalley and Herlyn,
2009; Kuphal and Bosserhoff, 2009). Tumor-initiating cells
share key characteristics of stem cells; i.e., they are able to
self-renew and to differentiate into malignant and benign
cells. However, they differ from normal stem cells in that they
have escaped physiological growth control and are highly
drug resistant, survive chemotherapy, and subsequently drive
tumor recurrence and metastatic disease (Al-Hajj et al., 2003;
Ricci-Vitiani et al., 2007; Schatton and Frank, 2007; Smalley
and Herlyn, 2009). In addition, a low proliferation index, as
well as the presence of stem cell-associated markers such as
Notch receptors, Wnt proteins, the CD133 (prominin-1) stem
cell antigen, or nestin, has been detected in tumor-initiating
cells (Weeraratna et al., 2002; Balint et al., 2005; Klein et al.,
2007; Zabierowski and Herlyn, 2008; Refaeli et al., 2009; Al
Dhaybi et al., 2010). Recently, also in metastatic melanoma,
a subset of melanoma cells endowed with the capacity
to regenerate tumors and to promote metastasis was
identified (Rappa et al., 2008; Schatton et al., 2008; Refaeli
et al., 2009). These melanoma-initiating cells express the
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multidrug-resistant transporter ABCB5, conferring on them
resistance to chemotherapy, as well as the stem cell markers
CD133 and nestin, which seem to be of functional relevance
for melanoma-initiating cells, given that blocking CD133 or
ABCB5 reduced the capacity of melanoma cells to meta-
stasize (Rappa et al., 2008; Schatton et al., 2008; Fusi et al.,
2010).
In this study, we determined that RANK is expressed on
circulating melanoma cells. Our data suggest that RANK
expression might be involved in the development and
maintenance of melanoma-initiating cells.
RESULTS
RANK expression is upregulated in peripheral nucleated
blood cells from MM stage IV patients
We sought to investigate whether RANK–RANKL signaling
might have a role in metastasis of skin cancer. Therefore, we
first quantified the RANK and RANKL messenger RNA
(mRNA) expression in peripheral nucleated blood cells from
MM stage I patients without metastases and MM stage IV
patients presenting with multiple metastases in different
organs. Whereas we detected equal levels of RANK mRNA
in peripheral nucleated blood cells from MM stage I patients
and healthy donors, the RANK expression was significantly
increased in MM stage IV patients (Figure 1a). In contrast, we
did not observe upregulated RANKL mRNA levels in MM
stage IV compared with MM stage I patients or healthy donors
(Figure 1b). As RANK is also expressed by antigen-presenting
cells or monocytes and as RANKL can be found on activated
T cells (Walsh and Choi, 2003), we sorted HLA-DRþ
dendritic cells, CD14þ monocytes, CD3þ T cells, and
melanoma cells from the peripheral blood of healthy donors
and MM stage I and MM stage IV patients. Strikingly, the
RANK mRNA levels were increased in melanoma cells from
MM stage IV patients compared with MM stage I patients,
whereas we observed a similar RANK expression in dendritic
cells or monocytes from the same patients (Figure 1c). Next,
we analyzed RANK and RANKL expression in peripheral
nucleated blood cells from patients with nonmelanoma skin
cancers, such as basal cell carcinomas or squamous cell
carcinomas, which are known to metastasize less frequently
in immunocompetent patients (Weinberg et al., 2007). As
depicted in Figure 1d, neither RANK nor RANKL expression
was upregulated in peripheral nucleated blood cells from
basal cell carcinoma or squamous cell carcinoma patients
compared with healthy donors.
Melanoma cells expressing RANK are increased in the
peripheral blood of MM stage IV patients
Next, we analyzed whether the increase in RANK mRNA
levels that we detected in sorted melanoma cells from MM
stage IV patients (Figure 1c) could be attributed to elevated
protein expression. Hence, flow cytometry was performed
and melanoma cells in peripheral blood were identified by
the expression of the melanocyte-specific markers MART-1
and tyrosinase (Fusi et al., 2010). In all MM stage IV patients,
MART-1þ and tyrosinaseþ cells were detectable (Supple-
mentary Figure S1a online), whereas we identified melanoma
cells in only 11 of 45 MM stage I patients. Moreover, the total
numbers of MART-1þ cells in peripheral blood from MM
stage IV patients were significantly elevated compared with
stage I patients (Supplementary Figure S1b online). To
exclude cells of the hematopoietic lineage during analysis
of RANK expression on melanoma cells, CD45 staining was
performed and the numbers of RANKþ melanoma cells were
quantified in the CD45 nonhematopoietic subset.
CD45MART-1þ melanoma cells from the peripheral blood
of MM stage IV patients showed an increased RANK
expression compared with melanoma cells from stage I
patients (% CD45MART-1þ cells coexpressing RANK: stage
I patients 11.2±3.7%, stage IV patients 28.6±6.1%; Figure
2a), suggesting that, similar to the observations made in
prostate or breast cancer cells (Jones et al., 2006), the RANK
expression on melanoma cells might correlate with advanced
disease and metastasis formation. Of note, the RANK
expression on melanoma cells was not dependent on the
age of patients or the localization of the primary tumor.
Furthermore, the levels of RANK-expressing melanoma cells
did not differ significantly when comparing MM stage IV
patients with high versus low tumor burden at the time of
analysis. However, whereas chemotherapy, radiation ther-
apy, or a combination of both did not alter the RANK
expression on melanoma cells, immunotherapy increased the
levels of MART-1þRANKþ melanoma cells in peripheral
blood (0.71±0.13% from total peripheral nucleated blood
cells at the beginning of immunotherapy vs. 1.14±0.36%
after 12 months of treatment; n¼6 patients).
In contrast, the RANKL expression was not upregulated in
CD45MART-1þ melanoma cells from the peripheral blood
of MM stage IV patients compared with melanoma cells from
stage I patients (Figure 2b). Given that RANKL can be cleaved
from the cell surface and exist as a soluble ligand (Blair et al.,
2007), we performed ELISAs to detect soluble RANKL in the
serum. Similar to the gene expression and flow cytometry data
(Figures 1b and 2b), RANKL serum levels were very similar in
MM stage I and stage IV patients (0.16±0.10 pmol l1 in
healthy donors, 0.11±0.09pmol l1 in MM stage I patients,
and 0.15±0.13 pmol l1 in MM stage IV patients), demon-
strating that RANKL expression in melanoma cells appears to
have a rather minor role in advanced disease.
RANK-expressing melanoma cells are increased in metastases
compared with primary tumors
Next, we analyzed whether RANK-expressing melanoma
cells could be detected in primary tumors and in metastases
from MM patients. Therefore, immunofluorescence staining
was performed using antibodies directed against MART-1 and
RANK. The total numbers of MART-1þ melanoma cells per
0.5mm2 were similar in primary tumors from MM stage I and
MM stage IV patients (Figure 3a and b), whereas we found
decreased numbers of MART-1þ melanoma cells in lymph
node metastases from MM stage IV patients compared with
primary tumors of the same patients. As shown in Figure 3a,
melanoma cells from primary tumors of MM stage I patients
did not coexpress RANK. However, we identified a subset of
MART-1þ cells coexpressing RANK in primary tumors from
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MM stage IV patients (Figure 3a and c). Notably, the numbers
of MART-1þRANKþ melanoma cells were increased in
lymph node metastases from MM stage IV patients compared
with primary tumors of the same patient (% MART-1þ
RANKþ cells: primary tumors from MM stage I patients
0.18±0.12%, primary tumors from MM stage IV patients
1.98±0.31%, lymph node metastases from MM stage IV
patients 3.59±0.26%; Figure 3a and c). Together, these data
indicate that RANK expression on MART-1þ melanoma cells
seems to be associated with metastasis formation.
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Figure 1. Increased RANK expression in melanoma cells from malignant melanoma (MM) stage IV compared with MM stage I patients. (a, b) Quantitative
real-time PCR of receptor activator of NF-kB (RANK) (a) and receptor activator of NF-kB ligand (RANKL) (b) gene expression in peripheral nucleated blood
cells from healthy donors (n¼ 15), MM stage I patients (n¼ 37), and MM stage IV patients (n¼ 40). *Po0.05 versus MM stage I patients. (c) Quantitative
real-time PCR of RANK and RANKL mRNA expression in sorted dendritic cells, monocytes, T cells, and melanoma cells from the peripheral blood of healthy
donors, MM stage I patients, and MM stage IV patients. One representative out of three independent experiments is depicted. Histogram overlays from a MM
stage IV patient are depicted to demonstrate the purity of sorted cell populations. (d) Quantitative real-time PCR of RANK (left) and RANKL (right) gene
expression in peripheral nucleated blood cells from healthy donors (n¼ 8), basal cell carcinoma patients (n¼7), and squamous cell carcinoma patients (n¼ 7).
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RANK expression on melanoma cells does not promote bone
metastasis
Because it has been demonstrated that RANK expression
stimulates the migration of tumor cells toward bone and
promotes bone metastasis in breast, prostate, kidney, and
liver cancer patients (Chen et al., 2006; Jones et al., 2006;
Sasaki et al., 2007; Mikami et al., 2009; Mori et al., 2009), we
investigated whether the RANK expression on melanoma
cells from MM stage IV patients presenting with bone
metastases was increased compared with stage IV patients
without bone metastases. Therefore, we quantified the RANK
mRNA levels in peripheral nucleated blood cells from MM
stage IV patients with and without bone metastases. As
depicted in Figure 4a, gene expression levels were similar in
both cohorts. Moreover, immunofluorescence staining of
primary tumors from MM stage IV patients with and without
bone metastases revealed equal numbers of RANK-expressing
melanoma cells in primary melanoma tissue (Figure 4b). In
addition, we did not observe differences in the total numbers
of MART-1þ melanoma cells coexpressing RANK in the
CD45 nonhematopoietic subset of peripheral nucleated
blood cells from MM stage IV patients without bone
metastases compared with MM stage IV patients with bone
metastases (Figure 4c), suggesting that RANK expression has a
minor role in melanoma cell migration toward bone tissue.
RANK-expressing melanoma cells have a phenotype of
tumor-initiating cells
As RANK expression triggers metastasis formation in human
epithelial cancer and has been shown to correlate with more
aggressive and metastatic carcinomas (Chen et al., 2006;
Jones et al., 2006), and as we could show that RANK is
upregulated on melanoma cells from MM stage IV patients
with advanced disease, we speculated that RANK-expressing
melanoma cells might be able to initiate tumor formation and
tumor growth. Hence, we quantified the expression of the
melanoma stem cell marker ABCB5 in MART-1þRANKþ
melanoma cells. Interestingly, a substantial amount of MART-1þ
RANKþ melanoma cells in primary tumors and lymph node
metastases from MM stage IV patients coexpressed ABCB5
(Figure 5a and b). Because it is known that melanoma cells
can downregulate MART-1 to escape antitumoral immune
responses (Maeurer et al., 1996), the numbers of MART-1
cells coexpressing RANK and ABCB5 were quantified in
primary melanomas and lymph node metastases from MM
stage IV patients. However, we detected only a small subset
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Figure 2. RANK expression is upregulated in nonhematopoietic melanoma cells from MM stage IV patients compared with malignant melanoma (MM) stage I
patients. (a, b) MART-1þ melanoma cells in peripheral blood from MM stage I (n¼5) and stage IV patients (n¼ 5) were analyzed for receptor activator of
NF-kB (RANK) (a) and receptor activator of NF-kB ligand (RANKL) (b) expression by flow cytometry. Representative dot plots gated for CD45þ hematopoietic
and CD45 nonhematopoietic cells, as well as statistical evaluation of the percentage of CD45MART-1þ cells coexpressing either RANK (a) or RANKL
(b) are shown. *Po0.05 versus MM stage I patients. MART-1 staining was performed after cell permeabilization.
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of MART-1RANKþABCB5þ cells (Figure 5b), pointing to a
rather minor role of MART-1 melanoma cells in disease
progression and metastasis in the patients analyzed in this
study. Together, these data indicate that RANK is present
on MART-1þ melanoma-initiating cells; furthermore, they
suggest that RANK expression might be involved in the
development or maintenance of melanoma-initiating cells.
To examine this hypothesis, we quantified the MART-
1þRANKþABCB5þ melanoma cells in peripheral blood
from MM patients. MART-1þRANKþ and MART-1þRANK
melanoma cells were sorted from the peripheral blood of MM
stage IV patients and analyzed for the expression of ABCB5.
Strikingly, the majority of MART-1þRANKþ melanoma cells
coexpressed ABCB5, whereas only a small subpopulation of
MART-1þRANK melanoma cells from the same patients
showed an upregulation of the melanoma stem cell marker
(Figure 5c), demonstrating that RANK is present on melano-
ma-initiating cells (MART-1þRANKþ cells coexpressing
ABCB5: 79.9±6.3%; MART-1þRANK cells coexpressing
ABCB5: 7.1±2.0%). To further confirm the stem cell-like
phenotype of RANK-expressing melanoma cells, we investi-
gated the expression of CD133, given that CD133 is
considered a key cancer stem cell marker (Rappa et al.,
2008). As depicted in Figure 5d, nonhematopoietic MART-
1þRANKþ melanoma cells from the peripheral blood of MM
stage IV patients showed increased CD133 levels, whereas
we detected a significantly reduced CD133 expression in
CD45MART-1þRANKþ melanoma cells from MM stage I
patients (Figure 5d), again demonstrating that RANK is
expressed on melanoma-initiating cells. As melanoma-
initiating cells, in accordance with other known tumor stem
cells, are characterized by reduced proliferation (Schatton
et al., 2008; Al Dhaybi et al., 2010), we performed Ki67
staining to assess the proliferation index of nonhematopoietic
MART-1þRANKþ melanoma cells. Notably, we detected
increased numbers of RANKþKi67 melanoma cells in MM
stage IV patients compared with MM stage I patients, whereas
the levels of RANKþKi67þ melanoma cells were reduced in
MM stage IV compared with stage I patients (Figure 6a and b).
Of note, the majority of RANKþKi67 melanoma cells from
MM stage IV patients coexpressed CD133 (Figure 6c), again
pointing to a tumor stem cell-like phenotype in MART-
1þRANKþ melanoma cells.
RANK-expressing melanoma cells induced tumors in
immunodeficient mice
Next, we analyzed whether RANK-expressing melanoma
cells might be able to initiate melanoma growth in vivo.
MART-1þRANKþ and MART-1þRANK cells were sorted
from the peripheral blood of MM stage IV patients and
injected subcutaneously into immunodeficient NSG mice.
Notably, recipients that were inoculated with MART-
1þRANKþ melanoma cells developed tumors whereas we
did not detect solid tumors in recipients of MART-1þRANK
melanoma cells (Figure 6d), demonstrating that RANK-
expressing melanoma cells, in contrast to RANKMART-1þ
cells, are able to initiate tumor formation in vivo. Together,
our data show that RANK is expressed on melanoma-
initiating cells and might be crucial for melanoma stem cell
maintenance and therefore for metastatic tumor develop-
ment.
DISCUSSION
The results of this study demonstrate that RANK, a marker that
has previously been associated with metastasis in breast and
prostate cancer (Jones et al., 2006), was expressed on
melanoma cells from primary tumors and lymph node
metastases of MM stage IV patients. Moreover, RANK-
expressing MART-1þ melanoma cells exhibited a tumor
stem cell–like phenotype, suggesting that RANK expression
might have a role in the maintenance of melanoma-initiating
cells and therefore in metastasis formation and the spread of
disease.
Cancer metastasis is not a random process, and it is well
known that different cancer types have favorite metastatic
sites (Moore, 2001; Ben-Baruch, 2008; Herlyn, 2009).
Prostate cancer, for example, preferentially forms metastases
in bone, whereas breast cancer metastasizes to regional
lymph nodes, lung, liver, and bone (Ben-Baruch, 2008;
Herlyn, 2009). Skin tumors such as MM have a metastatic
pattern similar to that of breast cancer, but they also show
a high incidence of cutaneous metastases (Moore, 2001).
The RANK–RANKL pathway has been shown to be crucial for
metastasis in which the soluble cytokine RANKL, present at
high concentrations in the target organs, triggers the
migration of cancer cells expressing the receptor RANK
(Jones et al., 2006). In breast cancer patients, for instance, a
positive correlation of RANK-expression levels on tumor cells
with an increased metastatic phenotype has been reported
(Bhatia et al., 2005). Furthermore, upregulated RANK
expression was observed in biopsies from prostate cancer
patients and elevated RANK levels correlated with more
aggressive, advanced, and metastatic prostate carcinomas
(Chen et al., 2006). In accordance with these findings, we
detected an increased expression of RANK in primary tumors
and in lymph node metastases from MM stage IV patients
versus MM stage I patients (Figure 3), indicating that, similar
to the observations made in breast and prostate cancer,
Figure 3. Receptor activator of NF-jB (RANK)-expressing melanoma cells are present in primary melanomas and lymph node (LN) metastases from malignant
melanoma (MM) stage IV patients. (a) Immunofluorescence staining of melanoma tissue using antibodies directed against MART-1 and RANK. Cells expressing
both markers are marked by arrows. Original magnification  100 (hematoxylin and eosin (H&E) staining) or 400 (immunofluorescence staining),
bar¼ 25 mm. (b, c) Statistical evaluation of MART-1 and RANK expression in melanoma tissue. Total numbers of MART-1þ cells (b) and percentages of MART-
1þ cells coexpressing RANK (c) were quantified in primary tumor tissues from MM stage I (n¼7), or MM stage IV patients (n¼7), and in lymph node metastases
from MM stage IV patients (n¼ 7). *Po0.05 versus primary tumors of the same stage IV patients.
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RANK was upregulated in metastatic compared with non-
metastatic melanoma. Likewise, elevated levels of MART-1þ
melanoma cells coexpressing RANK were present in periph-
eral blood from MM stage IV patients presenting with
multiple metastases (Figure 2a), suggesting that in MM as
well, the RANK–RANKL signaling pathway might be critically
involved in tumor cell migration and metastasis formation.
This hypothesis was further strengthened by the fact that
RANK expression was not upregulated in patients with basal
cell or squamous cell carcinomas, two examples of skin
tumors that have been shown to metastasize less frequently in
immunocompetent patients (Figure 1d; Weinberg et al., 2007).
In breast or prostate cancer, expression of RANK on tumor
cells mediates metastasis to bone, because RANKL, as an
osteoclast differentiation factor, is highly upregulated in
bone marrow and triggers the migration of RANK-expressing
tumor cells toward bone tissue (Lacey et al., 1998; Jones
et al., 2006). However, the numbers of MART-1þRANKþ
melanoma cells and the RANK gene expression levels
were similar in primary tumors and metastases from MM
stage IV patients with bone metastases compared with MM
stage IV patients without bone metastases, suggesting that
in MM additional factors might be necessary to mediate
metastasis toward bone tissue. Notably, in contrast to pro-
state cancer cells, MART-1þ melanoma cells expressed only
feeble levels of RANK; moreover, the percentage of tumor
cells coexpressing RANK was markedly lower in primary
melanomas than in primary prostate carcinomas (Jones et al.,
2006; Armstrong et al., 2008; Penno et al., 2009), possibly
explaining the observation that melanoma, in contrast to
prostate cancer, does not preferentially metastasize to bone
tissue.
Melanoma progression and metastatic spread are driven
by a small population of tumor-initiating cells that migrate
from the primary lesion into surrounding tissues, blood, and
lymph vasculature (Schatton and Frank, 2007; Smalley and
Herlyn, 2009; Kuphal and Bosserhoff, 2009). Melanoma-
initiating cells are highly drug resistant and are characterized
by the expression of stem cell markers such as CD133 (Klein
et al., 2007; Schatton and Frank, 2007; Zabierowski and
Herlyn, 2008; Smalley and Herlyn, 2009). Interestingly,
MART-1þRANKþ melanoma cells from the peripheral blood
of MM stage IV patients expressed CD133, whereas CD133
expression was not detectable in MART-1þRANK melano-
ma cells from the same patient (Figure 5d), suggesting that
MART-1þRANKþ melanoma cells might represent tumor-
initiating cells.
However, CD133 did not accurately identify melanoma-
initiating cells, as both CD133þ and CD133 subpopulations
contained high frequencies of tumorigenic cells (Quintana
et al., 2008). Recently, the ATP-binding cassette transporter
ABCB5 was identified on a subset of CD133þ melanoma
cells, and only ABCB5þ cells were able to induce
melanomas in immunodeficient mice (Schatton et al.,
2008). Notably, the majority of MART-1þRANKþ melanoma
cells from peripheral blood andB60% of MART-1þRANKþ
melanoma cells from primary melanomas or lymph node
metastases of MM stage IV patients coexpressed ABCB5
(Figure 5a and b), suggesting that MART-1þRANKþ mela-
noma cells might in fact exhibit the characteristics of
melanoma-initiating cells that could be involved in meta-
static spread of the tumor. This suggestion was further
confirmed by the reduced Ki67 proliferation index in
RANKþMART-1þ melanoma cells compared with MART-
1þRANK cells from the same MM stage IV patient (Figure 6).
Of note, decreased cell proliferation compared with non-
tumorigenic cells is highly characteristic of melanoma-
initiating cells (Al Dhaybi et al., 2010). Moreover, MART-1þ
RANKþ melanoma cells from the peripheral blood of MM
stage IV patients were able to initiate tumor growth in
immunodeficient mice, clearly pointing to a tumor stem cell-
like phenotype.
Together, our data demonstrate that RANK is expressed in
metastatic melanoma and highly upregulated on a subset of
melanoma cells that exhibit the characteristics of melanoma-
initiating cells, strongly suggesting that RANK might play a
role in the development, maintenance, or migration of
melanoma-initiating cells and therefore in metastatic spread
of the tumor.
MATERIALS AND METHODS
Isolation of peripheral nucleated blood cells
After written informed consent had been obtained, peripheral
nucleated blood cells were isolated from 30ml EDTA-anticoagulated
peripheral blood of healthy donors (n¼ 25), melanoma patients
(n¼ 85), basal cell carcinoma (n¼ 7) and squamous cell carcinoma
patients (n¼ 7) by Ficoll gradient centrifugation (Ficoll reagent was
purchased from PAA, Pasching, Austria). Melanoma patients used for
this study were classified as stage I (n¼ 45) or stage IV (n¼ 40, 7 of
them presenting with bone metastases) according to the criteria of
the American Joint Committee on Cancer (Mohr et al., 2009) and
were either untreated, had undergone chemotherapy or radiation
therapy, or had received high-dose IFN-a (immunotherapy).
Peripheral nucleated blood cells were subjected to cell sorting,
FACS analysis, or quantitative real-time PCR. All experiments were
approved by the ethics committee of the University of Mu¨nster
Medical School (2006-542-f-S), and the study was conducted
according to the Declaration of Helsinki Principles.
Figure 4. Receptor activator of NF-jB (RANK) is not increased in malignant melanoma (MM) stage IV patients presenting with bone metastases. (a) RANK
gene expression levels in peripheral nucleated blood cells from MM stage IV patients with (n¼ 7) and without (n¼ 11) bone metastases were quantified by
real-time PCR. (b) RANK expression in melanoma cells of primary tumors from MM stage IV patients with and without bone metastases (n¼ 7 patients
each group) was analyzed by immunofluorescence staining using antibodies against RANK and MART-1. One representative image is shown, original
magnification  100 (hematoxylin and eosin (H&E) staining) or  400 (immunofluorescence staining), bar¼25 mm. (c) FACS analysis of MART-1þ melanoma
cells coexpressing RANK in peripheral blood from MM stage IV patients with and without bone metastases (n¼ 5 patients each group). MART-1 staining was
performed after cell permeabilization.
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a
Figure 5. MART-1þRANKþ melanoma cells coexpress the tumor stem cell markers ABCB5 and CD133. (a) Immunofluorescence staining of human skin,
primary tumors, and lymph node (LN) metastases using antibodies against MART-1, receptor activator of NF-kB (RANK), and ATP-binding cassette (ABC) B5.
Cells expressing all three markers are marked, original magnification  400, bar¼ 25 mm. (b) Statistical evaluation of MART-1þRANKþ melanoma cells
coexpressing ABCB5 and MART-1 cells coexpressing RANKþABCB5 in primary tumors and lymph node (LN) metastases from MM stage IV patients (n¼ 5
patients). (c) Immunofluorescence staining of MART-1þRANK and MART-1þRANKþ cells from peripheral blood of malignant melanoma (MM) stage IV
patients (n¼ 3). Representative merged images are shown, MART-1þ melanoma cells coexpressing ABCB5 are marked and anti-MART-1 staining was
performed after cell permeabilization. (d) FACS analysis of peripheral nucleated blood cells from MM stage I (n¼ 4) and MM stage IV patients (n¼ 4) using
antibodies against CD45, MART-1, RANK, and CD133. One representative histogram overlay and the statistical evaluation is shown (*Po0.05 vs. MM stage I
patients). MART-1 staining was performed after cell permeabilization.
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Flow cytometry
Expression of cell surface or intracellular markers was analyzed by
multicolor flow cytometry on a FACScalibur (BD, Heidelberg,
Germany) using the CellQuestPro software. Cells were stained with
the following monoclonal antibodies: FITC-conjugated anti-HLA-DR
(clone L243), anti-CD3 (clone UCHT1, both purchased from BD),
PE-conjugated anti-MART-1/Melan-A (clone A103, purchased from
Santa Cruz Biotechnology, Santa Cruz, CA), anti-CD14 (clone M5E2,
obtained from BD); PerCP-conjugated anti-CD45 (clone HI30
purchased from Biolegend, San Diego, CA), biotin-conjugated anti-
RANK (clone BAF683, purchased from R&D Systems, Wiesbaden,
Germany), or anti-RANKL (clone MIH24, purchased from NatuTec,
Frankfurt, Germany). Anti-human ABCB5 (clone ab77549) and
anti-human CD133 (clone ab19898) were obtained from Abcam
(Cambridge, MA). Anti-human tyrosinase (clone T311) was pur-
chased from Biomol (Hamburg, Germany), and anti-human mela-
noma-discriminated antigen (clone PAL-M1) was obtained from
Thermo Scientific (Rockford, IL). Allophycocyanin- or PerCP-
conjugated streptavidin as well as FITC-conjugated anti-mouse or
anti-goat IgG and FITC- or AlexaFluor 647-conjugated anti-rabbit
IgG secondary antibodies were obtained from Invitrogen (Karlsruhe,
Germany). Isotype-matched controls were included in each staining.
Intracellular MART-1 and tyrosinase staining was performed after
cell permeabilization using the Fixperm Set (Biolegend). Briefly, cells
were fixed and permeabilized in 0.1% saponin and 0.09% sodium
azide for 1 hour at 4 1C, washed three times, and subsequently
stained with 1 mg anti-MART-1 or anti-tyrosinase antibodies for
1 hour at 4 1C. To avoid nonspecific binding, 2% mouse serum was
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Figure 6. Reduced Ki67 proliferation index in MART-1þRANKþ melanoma cells. (a) Peripheral nucleated blood cells from MM stage IV patients (n¼ 5) were
stained for CD45, MART-1, RANK, and Ki67 and analyzed by flow cytometry. Cells are gated for CD45MART-1þ and one representative dot plot is shown.
(b) Statistical evaluation of Ki67 expression in CD45MART-1þRANKþ cells (n¼4 patients each group), *Po0.05 versus MM stage I patients. (c) FACS
analysis of peripheral nucleated blood cells from MM stage I and stage IV patients (n¼ 5 patients each group) using antibodies against MART-1, Ki67, RANK,
and CD133. One representative dot plot and the statistical evaluation of RANKþKi67 cells coexpressing MART-1 and CD133 are shown (*Po0.05 vs. MM
stage I patients). MART-1 and Ki67 staining was performed after cell permeabilization. (d) MART-1þRANKþ melanoma cells initiate tumor growth in
immunodeficient NSG mice. Mice (n¼3) were inoculated with 2.5 104 MART-1þRANKþ or MART-1þRANK cells from the peripheral blood of MM
stage IV patients and one representative histological analysis of skin biopsies from recipients is depicted, original magnification  200, bar¼ 25 mm.
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added to each sample before the intracellular MART-1 or tyrosinase
staining.
Additional methods can be found in the Supplementary informa-
tion online.
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